GlassScriptPhysician profile
Albert M Salomon
NPI 1902887789
$2,730.98
in general payments reported to CMS, 2019-2025
28 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,325 · 2022: $646 · 2023: $155 · 2024: $245 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $494.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $413.98 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $383.90 | 2019-2025 | Repatha |
| Abbvie INC. | $169.54 | 2019-2023 | Qulipta, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $153.82 | 2022-2025 | |
| Novo Nordisk INC | $143.71 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $130.09 | 2019 | |
| Abbott Laboratories | $129.92 | 2022-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $105.76 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $80.92 | 2019 | |
| Lilly USA, LLC | $77.34 | 2023-2025 | Zepbound, Mounjaro |
| Medtronic, INC. | $51.33 | 2022-2025 | Inceptiv, Minimed 780g |
| Astellas Pharma US INC | $44.92 | 2024-2025 | Veozah |
| Axsome Therapeutics, INC. | $42.44 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $37.80 | 2019-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $30.39 | 2019 | |
| Phathom Pharmaceuticals, INC. | $29.87 | 2024-2025 | Voquezna |
| Antares Pharma, INC. | $29.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.85 | 2019 | |
| Merck Sharp & Dohme LLC | $25.99 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.53 | 2022 | |
| Ibsa Pharma INC. | $18.75 | 2025 | Licart, Flector, Tirosint |
| Glaxosmithkline, LLC. | $18.49 | 2023 | Shingrix |
| Alexion Pharmaceuticals, INC. | $17.57 | 2025 | Strensiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.09 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.42 | 2019 | |
| Gilead Sciences, INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Salomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.